Health startup Doctolib's valuation drops 38%

French health-care startup Doctolib has seen its valuation decrease by 38% in a recent secondary share sale, now valued at €3.6 billion. This marks a significant drop from its previous valuation of €5.8 billion in 2022. Employees and early investors sold shares worth approximately €300 million ($345 million). The valuation decline reflects a recalibration in the secondary market for private tech companies, potentially signaling broader market adjustments or specific concerns regarding Doctolib's growth trajectory or profitability.